You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bendamustine

Showing 26 - 50 of 372
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

Not yet recruiting
  • Marginal Zone Lymphoma
  • Mosunetuzumab + Lenalidomide
  • +3 more
  • (no location specified)
Aug 16, 2023

Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)

Active, not recruiting
Has Results
  • Mantle Cell Lymphoma
  • Bendamustine
  • +7 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Feb 2, 2022

Mantle Cell Lymphoma Trial in Seoul (RB/RBAC alternating, RB)

Not yet recruiting
  • Mantle Cell Lymphoma
  • RB/RBAC alternating
  • RB
  • Seoul, Gangnam-Gu, Korea, Republic of
    Samsung Medical Center
Apr 18, 2022

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Completed
Has Results
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +5 more
  • gemcitabine hydrochloride
  • bendamustine hydrochloride
  • Atlanta, Georgia
  • +1 more
Oct 21, 2021

Leukemia, Lymphocytic, Chronic, B-Cell Trial in Austria (Bendamustine, Alemtuzumab)

Completed
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Innsbruck, Tirol, Austria
  • +6 more
Feb 15, 2022

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

Lymphoma Trial in Beijing, Shanghai City, Seoul (Obinutuzumab, Glofitamab, Rituximab)

Recruiting
  • Lymphoma
  • Beijing, China
  • +2 more
Oct 12, 2023

Mantle Cell Lymphoma, Lymphoma Trial in United States (BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax))

Active, not recruiting
  • Mantle Cell Lymphoma
  • Lymphoma
  • BR-I (bendamustine, rituximab, ibrutinib)
  • VEN (Venetoclax)
  • Basking Ridge, New Jersey
  • +6 more
Feb 3, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab

Recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Dec 17, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed Trial in Tianjin (Zanubrutinib, Fludarabine,

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
  • Zanubrutinib, bendamustine, rituximab
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Mar 18, 2022

Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma Trial in Winston-Salem (CPI 613, Bendamustine)

Recruiting
  • Relapsed T-Cell Lymphoma
  • +2 more
  • CPI 613
  • Bendamustine
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
Aug 27, 2021

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022

Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting
  • Follicular Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 3, 2023

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma Trial in Atlanta (Bendamustine, Gemcitabine,

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Bendamustine
  • +2 more
  • Atlanta, Georgia
  • +1 more
Aug 25, 2021

Multiple Myeloma Trial in Berne (Melphalan, Bendamustine)

Completed
  • Multiple Myeloma
  • Berne, Switzerland
    Department for Medical Oncology University Hospital/Inselspital
Jul 29, 2021

Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)

Active, not recruiting
  • Chronic Lymphoid Leukemia
  • Bendamustine
  • +3 more
  • Dresden, Germany
  • +16 more
Nov 8, 2022

Multiple Myeloma, Chronic Kidney Disease Trial in United Kingdom (Bortezomib, Thalidomide, Bendamustine)

Completed
Has Results
  • Multiple Myeloma
  • Chronic Kidney Disease
  • Basingstoke, United Kingdom
  • +8 more
Jan 26, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia
  • (no location specified)
Nov 30, 2022

Ibrutinib Combined With Bendamustine and Rituximab in Newly

Recruiting
  • Mantle Cell Lymphoma (MCL)
    • Beijing, Beijing, China
      Peking University Third Hospital
    May 31, 2022

    Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

    Withdrawn
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • (no location specified)
    Jun 28, 2023

    Lymphoma, Mantle-Cell Trial in Czechia (Polatuzumab vedotin, Bendamustine Hydrochloride, Rituximab)

    Not yet recruiting
    • Lymphoma, Mantle-Cell
    • Polatuzumab vedotin
    • +2 more
    • Brno, Czechia
    • +6 more
    May 28, 2021

    Indolent Non-hodgkin Lymphoma Trial in München (Obinutuzumab, Bendamustine)

    Active, not recruiting
    • Indolent Non-hodgkin Lymphoma
    • München, Bavaria, Germany
      Klinikum der Universität München
    Jul 23, 2021

    Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Yamagata (OPB-111077)

    Recruiting
    • Relapsed or Refractory Diffuse Large B-cell Lymphoma
    • Yamagata, Japan
      Yamagata University Hospital
    Oct 22, 2021

    Diffuse Large B Cell Lymphoma Trial (Polatuzumab Vedotin)

    Withdrawn
    • Diffuse Large B Cell Lymphoma
    • Polatuzumab Vedotin
    • (no location specified)
    May 3, 2022

    Hodgkin Lymphoma Trial (favezelimab/pembrolizumab, bendamustine, gemcitabine)

    Not yet recruiting
    • Hodgkin Lymphoma
    • favezelimab/pembrolizumab
    • +2 more
    • (no location specified)
    Aug 18, 2022